The FDA has cleared an investigational new drug application for Oyster Point Pharma’s dry eye disease treatment OC-01, the company announced in a press release.
OC-01, a nicotine acetylcholine receptor agonist, is an investigational compound that stimulates natural tear film production via a nasal spray. This clearance will support ongoing phase 2 clinical trials of OC-01 and OC-02, a similar compound, for the treatment of signs and symptoms of dry eye disease, the release said. OC-02 received IND clearance in October 2017.
“Our innovative pharmaceutical approach leverages the